Amylin Pharmaceuticals Inc.'s FDA approval of Bydureon (exenatide extended-release) late last month was a long time coming. The company first applied for approval in 2009, requiring three attempts before the FDA finally signed off. Read More
Last week, the prostate cancer world was again abuzz with the possibility that men with advanced prostate cancer may soon have additional life-extending treatment options. Read More
Even prostate cancer drugs that overcome the challenges of crossover clinical trial design (see a related story on p. 2) and demonstrate overall survival face a tough road ahead. Read More
